These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 34957531)

  • 21. Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study.
    Joung KI; Park H; Park S; Shin JY; Kim YH
    BMC Pulm Med; 2023 Mar; 23(1):98. PubMed ID: 36949407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
    Cottin V; Richeldi L; Rosas I; Otaola M; Song JW; Tomassetti S; Wijsenbeek M; Schmitz M; Coeck C; Stowasser S; Schlenker-Herceg R; Kolb M;
    Respir Res; 2021 Mar; 22(1):84. PubMed ID: 33726766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.
    Richeldi L; Varone F; Bergna M; de Andrade J; Falk J; Hallowell R; Jouneau S; Kondoh Y; Morrow L; Randerath W; Strek M; Tabaj G
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies.
    Li DY; Liu X; Huang JY; Hang WL; Yu GR; Xu Y
    Ther Adv Respir Dis; 2024; 18():17534666241232561. PubMed ID: 38414439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.
    Matteson EL; Kelly C; Distler JHW; Hoffmann-Vold AM; Seibold JR; Mittoo S; Dellaripa PF; Aringer M; Pope J; Distler O; James A; Schlenker-Herceg R; Stowasser S; Quaresma M; Flaherty KR;
    Arthritis Rheumatol; 2022 Jun; 74(6):1039-1047. PubMed ID: 35199968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimating the effect of nintedanib on forced vital capacity in children and adolescents with fibrosing interstitial lung disease using a Bayesian dynamic borrowing approach.
    Maher TM; Brown KK; Cunningham S; DeBoer EM; Deterding R; Fiorino EK; Griese M; Schwerk N; Warburton D; Young LR; Gahlemann M; Voss F; Stock C;
    Pediatr Pulmonol; 2024 Apr; 59(4):1038-1046. PubMed ID: 38289091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.
    Wijsenbeek M; Kreuter M; Olson A; Fischer A; Bendstrup E; Wells CD; Denton CP; Mounir B; Zouad-Lejour L; Quaresma M; Cottin V
    Curr Med Res Opin; 2019 Nov; 35(11):2015-2024. PubMed ID: 31328965
    [No Abstract]   [Full Text] [Related]  

  • 29. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
    Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease.
    Hoffmann-Vold AM; Weigt SS; Saggar R; Palchevskiy V; Volkmann ER; Liang LL; Ross D; Ardehali A; Lynch JP; Belperio JA
    EBioMedicine; 2019 Dec; 50():379-386. PubMed ID: 31732480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective.
    Albera C; Verri G; Sciarrone F; Sitia E; Mangiapia M; Solidoro P
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis.
    Richeldi L; Kolb M; Jouneau S; Wuyts WA; Schinzel B; Stowasser S; Quaresma M; Raghu G
    BMC Pulm Med; 2020 Jan; 20(1):3. PubMed ID: 31914963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The dorsal muscle group area at the T12 vertebral level as a risk factor for tolerability of nintedanib in patients with idiopathic pulmonary fibrosis or other progressive fibrosing interstitial lung diseases.
    Ono M; Kobayashi S; Masakazu H; Ishida M; Sato H; Okutomo K; Shirai Y; Takahashi K; Yamada M; Fujino N; Yamanda S; Yanai M
    Medicine (Baltimore); 2024 Jul; 103(28):e38920. PubMed ID: 38996147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK.
    Rinciog C; Watkins M; Chang S; Maher TM; LeReun C; Esser D; Diamantopoulos A
    Pharmacoeconomics; 2017 Apr; 35(4):479-491. PubMed ID: 28039616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries.
    Hilberg O; Hoffmann-Vold AM; Smith V; Bouros D; Kilpeläinen M; Guiot J; Morais A; Clemente S; Daniil Z; Papakosta D; Fretheim H; Neves S; Alfaro TM; Antoniou KM; Valveny N; Asijee G; Soulard S; Wuyts W
    ERJ Open Res; 2022 Jan; 8(1):. PubMed ID: 35083316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases.
    Brown KK; Inoue Y; Flaherty KR; Martinez FJ; Cottin V; Bonella F; Cerri S; Danoff SK; Jouneau S; Goeldner RG; Schmidt M; Stowasser S; Schlenker-Herceg R; Wells AU
    Respirology; 2022 Apr; 27(4):294-300. PubMed ID: 35224814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
    Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
    [No Abstract]   [Full Text] [Related]  

  • 38. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
    Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
    Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.
    Flaherty KR; Wells AU; Cottin V; Devaraj A; Inoue Y; Richeldi L; Walsh SLF; Kolb M; Koschel D; Moua T; Stowasser S; Goeldner RG; Schlenker-Herceg R; Brown KK;
    Eur Respir J; 2022 Mar; 59(3):. PubMed ID: 34475231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis.
    Fukihara J; Kondoh Y
    Expert Rev Respir Med; 2016 Dec; 10(12):1247-1254. PubMed ID: 27744713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.